Glickman Urological and Kidney Institute, Cleveland Clinic, OH, USA.
BJU Int. 2011 Dec;108(11):1879-85. doi: 10.1111/j.1464-410X.2011.10120.x. Epub 2011 Mar 28.
What's known on the subject? and What does the study add? Laparoendoscopic single-site (LESS) nephrectomy is feasible to remove diseased kidneys. Most of such procedures previously reported were performed through a transperitoneal (trans-abdominal) approach. We report the feasibility, safety, and techniques of performing such operations without disturbing the bowels (a retroperitoneal LESS approach). This approach provides acceptable operative outcomes, and is especially valuable for patients who need to have an intact peritoneal envelope, or those with potentially abnormal or obliterated peritoneal space.
• To retrospectively review our experience with respect to evaluating the feasibility and safety of retroperitoneoscopic laparoendoscopic single-site surgery (LESS) nephrectomy. • To present the technical details of such a procedure.
• In total, eight retroperitoneoscopic LESS nephrectomies (in seven patients) were completed for a variety of indications in a single centre. • The GelPOINT apparatus (Applied Medical, Rancho Santa Margarita, CA, USA) was used as an access platform through a flank incision (3-5 cm). • Except for a bendable grasper and flexible vascular staplers, all instruments used were conventional straight laparoscopic instruments. • Perioperative data were retrospectively obtained for all patients, including demographic data, operative indications, operative records, length of stay, complications, and pathological analysis.
• All retroperitoneoscopic LESS nephrectomy procedures attempted were completed successfully without complications. No extra working port was required for any case. • Median (range) operating time was 164 (87-198) min and median (range) estimated blood loss was 50 (10-200) cm(3) . Median (range) length of hospital stay was 2 (1-3) days. • The median narcotic used was 34 mg of parental morphine sulphate equivalent. The median (range) visual analogue pain scale score at discharge was 2 (0-3) out of 10. • The present single arm observation study is limited by the small patient number and the absence of a control cohort.
• Retroperitoneoscopic LESS nephrectomy using the GelPOINT apparatus as an access platform is feasible and safe. • It provides adequate flexibility and spacing of port placements as well as acceptable operative outcomes. • It is especially valuable for those patients who need to maintain peritoneal integrity or those with an abnormal or obliterated peritoneal space.
•回顾我们评估后腹腔镜经皮肾镜单部位手术(LESS)肾切除术可行性和安全性的经验。•介绍该手术的技术细节。
•在一家中心共完成了 8 例(7 例患者)各种适应证的后腹腔镜经皮肾镜单部位肾切除术。•使用 GelPOINT 器械(Applied Medical,Rancho Santa Margarita,CA,USA)通过侧腹切口(3-5cm)作为进入平台。•除了弯曲抓钳和柔性血管吻合器外,所有使用的器械均为常规直式腹腔镜器械。•所有患者均回顾性获得围手术期数据,包括人口统计学数据、手术适应证、手术记录、住院时间、并发症和病理分析。
•所有尝试的后腹腔镜经皮肾镜单部位肾切除术均无并发症成功完成,无需为任何病例增加额外的工作端口。•中位(范围)手术时间为 164(87-198)min,中位(范围)估计出血量为 50(10-200)cm3。中位(范围)住院时间为 2(1-3)天。•中位使用的阿片类药物为 34mg 硫酸吗啡等效物。出院时中位(范围)视觉模拟疼痛评分为 2(0-3)/10。•本单臂观察研究受到患者数量少和缺乏对照组的限制。
•使用 GelPOINT 器械作为进入平台的后腹腔镜经皮肾镜单部位肾切除术是可行和安全的。•它提供了足够的灵活性和端口放置间距,以及可接受的手术结果。•对于需要保持腹膜完整性或腹膜空间异常或闭塞的患者尤其有价值。